Search for Clinical Trial Results
Neuromyelitis Optica Spectrum Disorder - 28 Studies Found
Status | Study |
Active, not recruiting |
Study Name: Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Condition:
|
Active, not recruiting |
Study Name: A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Condition:
|
Active, not recruiting |
Study Name: Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Condition:
Date: 2011-05-31 Interventions: Biological: human umbilical cord mesenchymal stem cells Participants will be given hUC-MSCs transplantat |
Recruiting |
Study Name: A Longitudinal Study of Neuromyelitis Optica and Transverse Myelitis Condition:
|
Recruiting |
Study Name: Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct Condition:
Date: 2009-12-02 |
NOT_YET_RECRUITING |
Study Name: Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA� During Pregnancy Condition: Date: 2024-05-18 Interventions: Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed.No study drug will be administered. |
NOT_YET_RECRUITING |
Study Name: Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders Condition: Date: 2024-05-18 Interventions: Inebilizumab: 300mg IV on Day1 and Day 15.The first dose of inelizumab is given during IVMP. |
RECRUITING |
Study Name: Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA� During Pregnancy Condition: Neuromyelitis Optica Spectrum Disorder Date: 2024-05-18 Interventions: Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed.No study drug will be administered. |